

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau

(43) International Publication Date  
13 June 2024 (13.06.2024)



(10) International Publication Number  
**WO 2024/124113 A1**

(51) International Patent Classification:

A61K 31/519 (2006.01) A61K 38/19 (2006.01)  
A61P 7/00 (2006.01) A61K 45/06 (2006.01)  
A61P 7/04 (2006.01) A61K 31/496 (2006.01)  
A61K 31/4152 (2006.01)

(21) International Application Number:

PCT/US2023/083090

(22) International Filing Date:

08 December 2023 (08.12.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/386,710 09 December 2022 (09.12.2022) US  
63/605,721 04 December 2023 (04.12.2023) US

(71) Applicant: **PRINCIPIA BIOPHARMA INC.** [US/US];  
55 Corporate Drive, Bridgewater, New Jersey 08807 (US).

(72) Inventors: **DAAK, Ahmed**; c/o Sanofi, Patent Department,  
450 Water Street, Cambridge, Massachusetts 02141 (US).

**KHAN, Umer**; c/o Sanofi, Patent Department, 450 Water  
Street, Cambridge, Massachusetts 02141 (US).

(74) Agent: **WINKLER, Lauren et al.**; 125 Cambridge Park  
Drive, Suite 301, Cambridge, Massachusetts 02140 (US).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,  
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,  
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,  
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,  
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,  
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,  
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,  
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,  
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,  
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, CV,  
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,  
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,

(54) Title: METHODS FOR TREATING IMMUNE THROMBOCYTOPENIA IN SUBJECTS WITH COGNITIVE IMPAIRMENT  
BY ADMINISTERING RILZABRUTINIB




Fig. 11

(57) Abstract: Methods for treating immune thrombocytopenia in a subject with cognitive impairment comprising administering at least one compound chosen from (R)-2-[3-[4-amino- 3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4- methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile (rilzabrutinib) and pharmaceutically acceptable salts thereof are disclosed.

[Continued on next page]

WO 2024/124113 A1

RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

— *of inventorship (Rule 4.17(iv))*

**Published:**

— *with international search report (Art. 21(3))*  
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*